Brief: Cyclo Therapeutics Provides Business Update And Reports First Quarter 2023 Financial Results
May 15 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS
FIRST
QUARTER 2023 FINANCIAL RESULTS
* CYCLO THERAPEUTICS - ENDED QUARTER ON A PRO FORMA BASIS
WITH
ABOUT $3.0 MILLION OF CASH
* CYCLO THERAPEUTICS - EXPECTS RESEARCH AND DEVELOPMENT
COSTS TO
INCREASE IN 2023 AS CO TO SEEK REGULATORY APPROVAL FOR USE OF
TRAPPSOL IN TREATMENT OF NPC & ALZHEIMER'S
Source text for Eikon: ID:nBwbshgYGa
Further company coverage: CYTH.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Rafael Holdings
See all newsBrief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million